Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Breast cancer: is the future of PARP inhibitors bright?
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Post-progression data confirm the benefits of novel combinations for EGFR-mutated NSCLC
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
Promising efficacy data reported for a targeted agent harbouring a MET alteration in NSCLC
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
How ‘precise’ has lung cancer treatment become?
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024